title: Clinical efficacy of sitafloxacin 100 mg twice daily for 7 days for patients with non-gonococcal urethritis.
abstract: To clarify the clinical efficacy of STFX for patients with non-gonococcal urethritis (NGU), including chlamydial urethritis and Mycoplasma genitalium-positive urethritis, this study included male patients with NGU who were 20 years old or older. The pathogens, including Chlamydia trachomatis, M. genitalium and Ureaplasma urealyticum, were detected by nucleic acid amplification tests and the patients were treated with sitafloxacin 100 mg twice daily for 7 days. Microbiological and clinical efficacies were assessed for the patients with NGU posttreatment. Among the 208 patients enrolled in this study, data for a total of 118 patients could be analyzed. The median age was 32 (20-61) years. The median duration from the completion of treatment to the second visit was 21 (14-42) days. There were 68 pathogen-positive NGU cases and 50 with NGU without any microbial detection. Microbiological cure was achieved in 95.6% of the pathogen-positive NGU patients. Total clinical cure was achieved in 91.3% (105/115). In this study, STFX was able to eradicate 95.7% of C. trachomatis, 93.8% of M. genitalium and 100% of U. urealyticum. The results of our clinical research indicate that the STFX treatment regimen should become a standard regimen recommended for patients with NGU. In addition, this regimen is recommended for patients with M. genitalium-positive NGU.
authors.affiliation: Department of Urology, Sapporo Medical University School of Medicine, S1, W16, Chuo-ku, Sapporo, 0608543, Japan, stakahas@sapmed.ac.jp.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Takahashi
authors.forename: Ryoichi
authors.initials: R
authors.lastname: Hamasuna
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Yasuda
authors.forename: Shin
authors.initials: S
authors.lastname: Ito
authors.forename: Kenji
authors.initials: K
authors.lastname: Ito
authors.forename: Shuichi
authors.initials: S
authors.lastname: Kawai
authors.forename: Takamasa
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: Takashi
authors.initials: T
authors.lastname: Satoh
authors.forename: Kenichi
authors.initials: K
authors.lastname: Sunaoshi
authors.forename: Koichi
authors.initials: K
authors.lastname: Takeda
authors.forename: Nobukazu
authors.initials: N
authors.lastname: Suzuki
authors.forename: Shinichi
authors.initials: S
authors.lastname: Maeda
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Nishimura
authors.forename: Souichirou
authors.initials: S
authors.lastname: Fukuda
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Matsumoto
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002692:Chlamydia trachomatis / Q000187:drug effects / Q000302:isolation & purification; D024841:Fluoroquinolones / Q000008:administration & dosage* / Q000009:adverse effects; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D045704:Mycoplasma genitalium / Q000187:drug effects / Q000302:isolation & purification; D011446:Prospective Studies; D016990:Ureaplasma urealyticum / Q000187:drug effects / Q000302:isolation & purification; D014526:Urethritis / Q000188:drug therapy* / Q000382:microbiology; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; C076246:sitafloxacin